CTOs on the Move

TLC Laser Eye Centers

www.tlcvision.com

 
TLC Laser Eye Centers is North America’s leading laser eye surgery provider, with more than 20 years of LASIK experience. Book a Free Consultation near you.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tlcvision.com
  • 5280, Solar Drive
    Mississauga, ON CAN L4W 5M8
  • Phone: 877.852.2020

Executives

Name Title Contact Details

Similar Companies

Rain Oncology

Rain Oncology is a clinical stage company researching, developing and translating innovative targeted therapies for patients with cancer.

RenalytixAI

Renalytix AI plc (LSE AIM: RENX) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease.

McKesson

McKesson Corporation, currently ranked 7th on the FORTUNE 500, we are a global healthcare services and medical supply company dedicated to delivering better care. We support the entire healthcare system, including pharmacies, hospitals, health systems, biotech and life sciences companies, specialty care and oncology practices, physician offices, surgery centers, and long-term care and home health facilities. We deliver pharmaceutical products, medical supplies and business services to each of these groups to create a world of better health.

Talia Technology (Marco Ophthalmic)

Talia Technology (Marco Ophthalmic Inc.) is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.